AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
178 hedge funds and large institutions have $1.01B invested in AMAG Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 55 increasing their positions, 70 reducing their positions, and 14 closing their positions.
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
8% more funds holding
Funds holding: 165 → 178 (+13)
2% less capital invested
Capital invested by funds: $1.03B → $1.01B (-$23.5M)
21% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 70
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
99% less call options, than puts
Call options by funds: $2.2M | Put options by funds: $197M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRC
North Run Capital
Boston,
Massachusetts
|
+$14M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$11M |
| 3 |
AG
Artal Group
Luxembourg
|
+$7.5M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$6.93M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$6.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$18.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.2M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$16.1M |
| 4 |
GCM
Greywolf Capital Management
Purchase,
New York
|
-$15.8M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$11.5M |
AMAG Hedge Fund Activity: Q3 2016 in Review
178 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2016, worth a combined $1.01B — down 2.3% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AMAG positions and 14 closed out — a net gain of 14 holders — while 55 added to existing stakes and 70 trimmed.
The largest buyer was North Run Capital, opening a new position worth an estimated $14M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $18.7M sold.
- 178 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2016, up from 165 in Q2 2016.
- Funds reported $1.01B of AMAG Pharmaceuticals stock for Q3 2016, down 2.3% quarter-over-quarter.
- 28 funds opened new AMAG Pharmaceuticals positions in Q3 2016 and 14 closed out, a net change of +14 holders.
- The largest AMAG Pharmaceuticals buyer in Q3 2016 was North Run Capital, an estimated $14M added.
- The largest AMAG Pharmaceuticals seller in Q3 2016 was EverPoint Asset Management, an estimated $18.7M sold.
Based on aggregated 13F filings for Q3 2016.